Nanjing Ningqi Pharmaceutical Technology

Nanjing Ningqi Pharmaceutical Technology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company's lead candidate, NQ0801, is an orally bioavailable small molecule GLP-1 receptor agonist designed to provide a more convenient alternative to injectable therapies for type 2 diabetes and obesity. Founded in 2017 by experienced industry veterans, Ningqi Pharma utilizes structure-based drug design and a proprietary R&D platform to target high-value biological pathways. The company is headquartered in Nanjing, China, and is supported by a strong base of venture capital investors as it advances its pipeline through clinical trials in both China and global markets.